Facebook Instagram Twitter Linkedin Youtube Podcast

Duchenne News Tags: Antisense Therapeutics

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FibroGen Italfarmaco NS Pharma PepGen Pliant Therapeutics PTC Therapeutics REGENXBIO Santhera Sarepta Therapeutics Solid Biosciences Wave Life Sciences
June 8, 2023

Antisense Announces First Patient Dosed in ATL1102 Phase IIb Duchenne Trial

Antisense Therapeutics announces that recruitment has commenced in the multicentre double-blind, placebo-controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne.
Read More
May 23, 2023

Antisense Receives Approval to Conduct Phase IIb Trial of ATL1102 and Appoints New CEO

Antisense announces approval to conduct phase 2b trial of ATL1102 and appoints CEO Dr. James Garner
Read More

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Gold Transparency 2022 Candid. Logo
Sitemap
© 2023 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)





    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Accessible Vehicle Fund Applications Open

    Apply Today